Therefore, we conducted RNA expression profiling of metastatic tumor tissues from matched patient biopsies before and after treatment with the AR signaling inhibitor enza, one of the principal treatments for mCRPC (Fig. 5A; ref. 62). This evidence concerns the gene AR and neoplasm.